856O - Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BR...

Date 07 October 2016
Event ESMO 2016 Congress
Session Gynaecological cancers
Topics Ovarian Cancer
Presenter Rebecca Kristeleit
Citation Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374
Authors R.S. Kristeleit1, R. Shapira-Frommer2, A. Oaknin3, J. Balmaña3, I.L. Ray-Coquard4, S. Domchek5, A.V. Tinker6, C.M. Castro7, S. Welch8, A.M. Poveda9, K. Bell-Mcguinn10, G. Konecny11, H. Giordano12, L. Maloney12, S. Goble13, L. Rolfe14, A. Oza15
  • 1Department Of Oncology, University College London, Cancer Institute, WC1E 6BT - London/GB
  • 2Medical Oncology, Sheba Medical Center, 5262100 - Ramat Gan/IL
  • 3Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 4Department Of Oncology, GINECO, Centre Léon Bérard and University Claude Bernard, Lyon/FR
  • 5Medical Oncology, University of Pennsylvania, Philadelphia/US
  • 6Department Of Medicine, British Columbia Cancer Agency, Vancouver/CA
  • 7Department Of Medicine, Gynecological Oncology, Massachusetts General Hospital, Harvard Medical School, Boston/US
  • 8Division Of Medical Oncology, London Regional Cancer Program, London/CA
  • 9Gynecology Department, Clinical Area Of Gynecologic Oncology, Valencian Institute of Oncology, Valencia/ES
  • 10Gynecologic Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York/US
  • 11Department Of Medicine, Hematology & Oncology, University of California Los Angeles (UCLA), Los Angeles/US
  • 12Clinical Science, Clovis Oncology, Inc., Boulder/US
  • 13Biostatistics, Clovis Oncology, Inc., Boulder/US
  • 14Executive Vp Of Clinical And Preclinical Development, Clovis Oncology, Inc., Boulder/US
  • 15Department Of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto/CA



Rucaparib has demonstrated clinical activity in BRCAmut HGOC in two phase 2 studies. Data from these studies were pooled to examine the clinical activity and safety of rucaparib in BRCAmut pts with HGOC who have received ≥2 prior chemotherapy (chemo) regimens.


Pts (n = 106) with BRCAmut relapsed, HGOC who received ≥2 prior chemo regimens and were enrolled in Study 10 part 2a (n = 42) or ARIEL2 part 1 or 2 (n = 64) by 1 Oct 2015 were included in the pooled efficacy analysis. The pooled safety dataset (n = 144) included 38 additional pts with


Median age was 59 years; median number of prior chemo regimens was 3. Median duration of treatment was 6.9 months. The investigator-assessed confirmed objective response rate (RECIST v1.1) was 54% in pts with ≥2 prior chemo regimens. The median duration of investigator-assessed confirmed response was 9.2 months (95% confidence interval: 6.6-11.7). Common treatment-emergent adverse events included asthenia/fatigue (78%; grade ≥3: 15%), nausea (76%; grade ≥3: 4%), anemia (51%; grade ≥3: 27%), vomiting (50%; grade ≥3: 6%), and transient increased ALT/AST (47%; grade ≥3: 13%). Five pts died as a result of disease progression.


Rucaparib has clinical activity and an acceptable safety profile in pts with BRCAmut HGOC who received ≥2 prior lines of chemo. The efficacy of rucaparib will be compared to standard chemo in a phase 3 study (ARIEL4).

Clinical trial identification

NCT01482715 (NIH), NCT01891344 (NIH)

Legal entity responsible for the study

Clovis Oncology, Inc.


Clovis Oncology, Inc.


R.S. Kristeleit: Consulting/Advisory role: Clovis Oncology, Roche/Genentech, Sotio, Lytix Biopharma; Travel, Accommodations, Expenses: Clovis Oncology, Basilea, PiQuR; Honoraria: Clovis Oncology, Roche/Genentech, AstraZeneca. A. Oaknin: Consulting or Advisory Role: AstraZeneca, PharmaMar, Clovis Oncology, Roche Glycart J. Balmaña: Consulting or Advisory Role - Clovis Oncology, Inc.; Speakers' Bureau: AstraZeneca; Travel Expenses: AstraZeneca. I.L. Ray-Coquard: Consulting or Advisory Role: PharmaMar, AstraZeneca, MSD, Roche Glycart; Travel, Accommodations, Expenses: PharmaMar, Roche Glycart. S. Domchek: Honoraria: EMD Serono; Research Funding: AstraZeneca, Clovis Oncology, Abbvie, Pharmamar. A.V. Tinker: Consulting or Advisory Role: AstraZeneca; Research Funding: AstraZeneca/MedImmune K. Bell-Mcguinn: Consulting or Advisory Role: Clovis Oncology, AstraZeneca; Travel, Accommodations, Expenses: Abbvie. G. Konecny: Consulting or Advisory Role: Novartis; Travel, Accommodations, Expenses: Novartis; Research Funding: Amgen, Pfizer. H. Giordano, L. Maloney, S. Goble, L. Rolfe: Employment: Clovis Oncology, Inc.; Stock and Other Ownership Interests: Clovis Oncology, Inc. A. Oza: Consulting or Advisory Role: Amgen, Verastem, Clovis Oncology, Immunovaccine; Travel, Accommodations, Expenses: AstraZeneca; Honoraria: WebRx; Research Funding: AstraZeneca, Roche, Merck, AstraZeneca. All other authors have declared no conflicts of interest.